Stoke Therapeutics, Inc.’s $163.3 Million Initial Public Offering

Davis Polk advised the representatives of the underwriters in connection with the transaction. Fenwick & West LLP advised Stoke Therapeutics on the deal.

The Stoke Therapeutic consisted of $163.3 million initial public offering of 9,074,776 shares of common stock of Stoke Therapeutics, Inc., which includes 1,183,666 shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. Stoke Therapeutics, Inc. is listed on the Nasdaq Global Select Market under the symbol “STOK.”

Based in Cambridge, Massachusetts, Stoke Therapeutics is a biotechnology company that is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health.

J.P. Morgan Securities LLC, Cowen and Company, LLC and Credit Suisse Securities (USA) LLC acted as representatives of the underwriters.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick (Picture) and associates Jennifer Ying Lan, Ariel Rivera and Meaghan Kennedy. Partner David R. Bauer and associate Michael V. Policastro provided intellectual property and technology advice. The tax team included partner Michael Mollerus and associate Dao Fu. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Dao Fu – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Meaghan Kennedy – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Michael Policastro – Davis Polk & Wardwell; Ariel Rivera – Davis Polk & Wardwell; Jennifer Ying Lan – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Canaccord Genuity; Cowen Inc.; Credit Suisse; J.P. Morgan Securities LLC;

Author: Ambrogio Visconti